247 related articles for article (PubMed ID: 23776379)
1. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.
Hund E
Appl Clin Genet; 2012; 5():37-41. PubMed ID: 23776379
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in transthyretin amyloidosis therapy.
Ueda M; Ando Y
Transl Neurodegener; 2014; 3():19. PubMed ID: 25228988
[TBL] [Abstract][Full Text] [Related]
3. Familial amyloid polyneuropathy.
Planté-Bordeneuve V; Said G
Lancet Neurol; 2011 Dec; 10(12):1086-97. PubMed ID: 22094129
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.
Dohrn MF; Röcken C; De Bleecker JL; Martin JJ; Vorgerd M; Van den Bergh PY; Ferbert A; Hinderhofer K; Schröder JM; Weis J; Schulz JB; Claeys KG
J Neurol; 2013 Dec; 260(12):3093-108. PubMed ID: 24101130
[TBL] [Abstract][Full Text] [Related]
6. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L
J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427
[TBL] [Abstract][Full Text] [Related]
7. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy.
Buxbaum JN
Degener Neurol Neuromuscul Dis; 2012; 2():165-173. PubMed ID: 30890886
[TBL] [Abstract][Full Text] [Related]
9. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
10. Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family.
Liu JY; Guo YJ; Zhou CK; Ye YQ; Feng JQ; Yin F; Jiang XM
J Neurol Sci; 2011 May; 304(1-2):83-6. PubMed ID: 21397913
[TBL] [Abstract][Full Text] [Related]
11. Extremely Early Onset Transthyretin Familial Amyloid Polyneuropathy with a Leu55Pro Mutation: A Pediatric Case Report and Literature Review.
Lee YJ; Oh J; Hwang SK; Lee EJ; Yang DH; Kim YJ; Kwon S; Hyun MC
Neuropediatrics; 2019 Oct; 50(5):322-326. PubMed ID: 31319424
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of familial amyloid polyneuropathy].
Adams D; Samuel D; Slama M
Presse Med; 2012 Sep; 41(9 Pt 1):793-806. PubMed ID: 22341949
[TBL] [Abstract][Full Text] [Related]
13. Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area.
Mazzeo A; Russo M; Di Bella G; Minutoli F; Stancanelli C; Gentile L; Baldari S; Carerj S; Toscano A; Vita G
J Neuromuscul Dis; 2015 Jul; 2(s2):S39-S48. PubMed ID: 27858761
[TBL] [Abstract][Full Text] [Related]
14. Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy.
Falcão de Campos C; Conceição I
Drug Healthc Patient Saf; 2023; 15():51-62. PubMed ID: 36824481
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the treatment of familial amyloid polyneuropathy.
Adams D
Ther Adv Neurol Disord; 2013 Mar; 6(2):129-39. PubMed ID: 23483184
[TBL] [Abstract][Full Text] [Related]
16. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
[TBL] [Abstract][Full Text] [Related]
18. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy.
Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y
J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783
[TBL] [Abstract][Full Text] [Related]
19. Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.
Escolano-Lozano F; Barreiros AP; Birklein F; Geber C
Brain Behav; 2018 Jan; 8(1):e00889. PubMed ID: 29568686
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
